Overall, chemical inhibition of CatB has been studied in a variety of diseases, includes trauma of cerebral bleeding, Huntington’s disease, excitatory epilepsy, inflammatory pain and neurodegenerative diseases [108]. Here, TYRP1 is linked to neurodegenerative disease.